DOCSLIB.ORG

| Hao Wakat I Akitolea Mai Mare Un Auto

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
| Hao Wakat I Akitolea Mai Mare Un Auto |HAO WAKAT I AKITOLEAUS009943514B2 MAIMARE UNAUTO (12 ) United States Patent ( 10 ) Patent No. : US 9 , 943 ,514 B2 Deaver et al. ( 45 ) Date of Patent: * Apr. 17, 2018 ( 54 ) METHODS FOR TREATING (52 ) U . S . CI. ANTIPSYCHOTIC - INDUCED WEIGHT GAIN CPC . .. .. A61K 31/ 485 (2013 .01 ) ; A61K 9 / 20 ( 2013 .01 ) ; A61K 31 /551 ( 2013 .01 ) (71 ) Applicant : Alkermes Pharma Ireland Limited , ( 58 ) Field of Classification Search Dublin ( IE ) CPC .. .. A61K 31/ 485 ; A61K 31 / 551; A61K 9 / 20 ( 72 ) Inventors : Daniel Deaver , Franklin , MA (US ) ; See application file for complete search history . Mark Todtenkopf, Franklin , MA (US ) ( 73) Assignee : Alkermes Pharma Ireland Limited , (56 ) References Cited Dublin (IE ) U . S . PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer, the term of this 8 , 778 , 960 B2 * 7 /2014 Deaver .. .. A61K 31 /439 514 /289 patent is extended or adjusted under 35 9 , 126 , 977 B2 * 9 / 2015 Deaver . .. .. .. A61K 31/ 439 U . S . C . 154 ( b ) by 0 days . 9 ,211 , 293 B2 * 12 / 2015 Deaver A61K 31 /485 This patent is subject to a terminal dis 9 ,517 , 235 B2 * 12 /2016 Deaver . .. .. A61K 31/ 439 claimer . OTHER PUBLICATIONS (21 ) Appl. No. : 15 /342 , 263 Science Daily plataforma Sinc ( 2012 ). * ( 22 ) Filed : Nov . 3 , 2016 * cited by examiner (65 ) Prior Publication Data US 2017 /0119757 A1 May 4 , 2017 Primary Examiner — Shirley V Gembeh ( 74 ) Attorney, Agent, or Firm — Elmore Patent Law Related U . S . Application Data Group , P . C .; Joseph Zucchero ; Carolyn Elmore (63 ) Continuation of application No . 14 /813 , 260 , filed on Jul. 30 , 2015 , now Pat. No . 9 ,517 ,235 , which is a continuation of application No. 14 / 297 , 171 , filed on (57 ) ABSTRACT Jun . 5 , 2014 , now Pat. No . 9 ,126 , 977 , which is a The present invention relates to the discovery of a novel continuation of application No . 13 /215 ,718 , filed on opioid modulator effective in reducing pharmacologically Aug . 23 , 2011 , now Pat. No . 8 ,778 , 960 . induced weight gain associated with atypical antipsychotic ( 60 ) Provisional application No . 61/ 376 , 120 , filed on Aug . use . The present invention provides methods of reducing 23 , 2010 . antipsychotic induced weight gain , methods for suppressing food intake and reducing ghrelin levels induced by atypical (51 ) Int. CI. antipsychotic medications in a patient . A61K 31 /485 ( 2006 . 01 ) A61K 9 / 20 ( 2006 . 01 ) A61K 31/ 551 ( 2006 . 01 ) 29 Claims, 6 Drawing Sheets atent Apr . 17 , 2018 Sheet 1 of 6 US 9 ,943 , 514 B2 * + Olanzapine * Olanzapine + Compound- 1 CumulativeWeightGain(9) Olanzapine Naltrexone * . wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww planning pampumpen 1 2 3 4 5 6 1 8 9 10 Treatment Day FIG . 1 atent Apr . 17 , 2018 Sheet 2 of 6 US 9 ,943 , 514 B2 pa WWWWWW ????? MT Naltrexone * Compound 1 0 .0 0. 5 1. 0 1. 5 2 . 0 Time (Hours ) FIG . 2 . atent Apr . 17 , 2018 Sheet 3 of 6 US 9 , 943 , 514 B2 259 - Vehicle - - - - - Olanzapine - + + Olanzapine + Compound 1 - - - - - - - %WeightChangea? RRRRRRRRR 1 4 7 10 13 16 19 22 25 28 Day FIG . 3 atent Apr . 17 , 2018 Sheet 4 of 6 US 9 ,943 , 514 B2 Olanzapine+Compound1 Vehicle Olanzapine FatSubcutaneous CTScanData:MeanFatContent FIG.4 FatAbdominal š š š š ne z Scan Baseline % atent Apr . 17 , 2018 Sheet 5 of 6 US 9 , 943, 514 B2 ( a ) Olanzapine Day 28 Baseline wwwwww * wwwwwwwwwwwwwwtoShare W ww mundummánmhmmmmmmmmmmmmmmmmmm 7cm * * (b ) Olanzapine + Compound 1 Day 28 Baseline wwwwwwwwwwwwwwwwwwww A.N bo m Li ·m wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww HE* * .N" Wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww FIG . 5 atent Apr . 17 , 2018 Sheet 6 of 6 US 9 ,943 , 514 B2 Olanzapine+Compound1 Vehicle Olanzapine ..TrigTrig SerumChemistry FIG.6 LDLLDL 1257 ? ? p /bu US 9 , 943 ,514 B2 METHODS FOR TREATING disorders . A recent study reported that young children who ANTIPSYCHOTIC - INDUCED WEIGHT GAIN take antipsychotics risk long term health risks associated with rapid weight gain , for example , metabolic changes that RELATED APPLICATIONS could lead to diabetes, hypertension and other illnesses . 5 (Varley et al. , JAMA . 2009 ; 302 ( 16 ) :1811 - 1812 ). This application is a continuation of U . S . application Ser. Excessive weight gain associated with atypical antipsy No. 14 / 813 , 260 , filed Jul. 30 , 2015 , which is a continuation chotic use is a significant issue given its impact on general of U . S . application Ser. No . 14 /297 , 171 , filed Jun . 5 , 2014 , health and psychological issues . Unwanted weight gain is now U . S . Pat. No. 9 , 126 , 977 , issued Sep . 8 , 2015 , which is 10 also one of the most common reasons for a patient' s non a continuation of U . S . application Ser. No. 13 /215 ,718 , filed compliance of an atypical antipsychotic administration Aug . 23 , 2011 , now U . S . Pat . No . 8 , 778, 960 , issued Jul. 15 , schedule , ultimately leading to the failure of the treatment . 2014 , which claims the benefit of U . S . Provisional Appli Therefore, there is a continuing need to identify and develop cation No . 61/ 376 , 120 , filed on Aug. 23 , 2010 . The entire more effective drug treatments for preventing or reducing teachings of the above applications are incorporated herein 15 this side effect of atypical treatment. by reference . SUMMARY OF INVENTION FIELD OF INVENTION Applicants have surprisingly discovered that compounds The present invention relates to medications used for 20 of Formula I are effective in reducing pharmacologically weight control . More particularly , the present invention induced weight gain associated with atypical antipsychotic relates to the use of a novel opioid receptor modulator to use . minimize weight gain associated with antipsychotic drugs. Formula I BACKGROUND OF INVENTION 25 23 Antipsychotic medications are among the most important RPR N therapeutic tools for treating various psychotic disorders . P There are two categories of antipsychotics, typical and atypical. Typical antipsychotics e . g . , haloperidol and chlo - 30 rpromazine, were first developed in the 1950 ' s and were used to treat psychosis , particularly schizophrenia . Common side effects of typical antipsychotics include: dry mouth , tremors , weight gain , muscle tremors , and stiffness . In 35 addition , typical antipsychotics yield extrapyramidal side wherein , effects . These side effects include : motor disturbances, par A is chosen from — CEO) NH , and CES)NH2 ; kinsonian effects, akathesia , dystonia , akinesia , tardive dys Rl and R are both hydrogen or taken together R and R ’ are kinesia , and neuroleptic malignant syndrome. Some of these 40 R3CO is ; chosen from hydrogen , alkyl, alkenyl, aryl, heterocy side effects have been described to be worse than the actual clyl and hydroxyalkyl; symptoms of schizophrenia . Atypical antipsychotics are R4 is chosen from hydrogen , hydroxy, amino , alkoxy , considered to be the first line of treatment for schizophrenia C , -C20 alkyl and C . - C20 alkyl substituted with hydroxy or because of the improved extrapyramidal side effect profile in carbonyl ; vchot- 45 R is selected from hydrogen , hydroxyl, alkoxy and alkyl; comparison to typical antipsychotics . Atypical antipsychot- 4 RÓ is chosen from hydrogen , hydroxy, alkoxy and ics are also associated with superior tolerability , adherence — NR10R11. and relapse prevention and have led to improved treatment or together , R and R form a carbonyl or a vinyl substituent ; for patients with serious mental illness . However , they are R10 and R11 are chosen independently from hydrogen , alkyl also associated with significant weight gain . Numerous 50 and aliphatic ; and , reports based on extensive clinical studies have reported that - -- - - - represents a single or double bond . 40 - 80 % of patients under chronic atypical antipsychotic As such , the present invention provides methods of reduc ing antipsychotic induced weight gain induced by atypical treatment experience substantial weight gain , ultimately antipsychotic medications in a patient. The method com exceeding their ideal body weight by 20 % (Umbricht et al. , 55 prises administration of a therapeutically effective amount of J Clin . Psychiatry 55 ( Suppl. B ) : 157 - 160 ; Baptista , Acta a compound of Formula I to the patient in need thereof , Psychiatr . Scand . 100 : 3 - 16 , 1999 ) . Weight gain was found to preferably , Compound 1 . be greatest with clozapine , olanzapine , risperidone , and In one aspect, the invention relates to the lowering of quetiapine , and less with aripiprazole and ziprasidone . ( Tay - circulating ghrelin levels and /or the levels of ghrelin in lor et al. , Acta Psychiatr Scand . 2001 February ; 103 ( 2 ) : 158 ). 60 gastrointestinal tracts . As such , the present invention is further directed to methods of suppressing food intake Weight gain associated with atypical antipsychotics comprising administering to the patient in need of treatment increases the risk of obesity in patients undergoing treat an effective amount of the compounds of Formula I , wherein ment. Obesity is a leading cause ofmortality as it frequently the increased appetite is induced by administration of an leads to conditions such as diabetes and cardiovascular 65 atypical antipsychotic . disorders . In addition , atypical antipsychotics are increas - In one embodiment, the induced weight gain is associated ingly prescribed to children and adolescents with psychiatric with administration of olanzapine , clozapine, risperidone , US 9 ,943 ,514 B2 quetiapine, aripiprazole , ziprasidone, and pharmaceutically
Load more

Recommended publications
  • Prevalence and Type of Potential Pharmacokinetic Drug-Drug Interactions in Old Aged Psychiatric Patients
    Contemporary Behavioral Health Care Research Article ISSN: 2058-8690 Prevalence and type of potential pharmacokinetic drug- drug interactions in old aged psychiatric patients Gudrun Hefner1,2*, Stefan Unterecker3, Nagia Ben-Omar4, Margarete Wolf4, Tanja Falter2, Christoph Hiemke1 and Ekkehard Haen4 1Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Germany 2Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Mainz, Germany 3Department of Psychiatry, Psychosomatics, and Psychotherapy, University Hospital of Würzburg, Germany 4Department of Psychiatry and Psychotherapy, University of Regensburg, Germany Abstract Purpose: The number of prescribed drugs increases with age, and resulting polypharmacy bears the risk of drug-drug interactions (DDI). We assessed the prevalence and type of cytochrome P450 (CYP) associated pharmacokinetic DDI that were considered as clinically relevant in elderly psychiatric patients under conditions of every day pharmacotherapy. Methods: For retrospective analysis a large therapeutic drug monitoring (TDM) data base was used. Patients included were elderly in- and outpatients, aged ≥ 65 years with a psychiatric disorder for whom serum level measurements of a psychotropic drug had been requested. Medication data were examined for co-prescription of clinically relevant CYP inhibitors or inducers and drugs that are substrates of these enzymes (victim drugs). Results: Data from 1243 patients (65.3% female) with a mean (± standard deviation) age of 73 ± 6 years were available for analysis. Mean number of prescribed drugs was 5.3 ± 3.4 per patient. Moderate (n=189, 73.8%) or strong (n=67, 26.2%) CYP inhibitors or inducers were prescribed in 18.9% of all patients. Most frequently prescribed CYP inhibitors were duloxetine (CYP2D6 inhibitor, n=73, 31.7%), melperone (CYP2D6 inhibitor, n=63, 27.4%) and omeprazole (CYP2C19 inhibitor, n=20, 8.7%).
    [Show full text]
  • Pharmacotherapy, Drug-Drug Interactions and Potentially
    medRxiv preprint doi: https://doi.org/10.1101/2021.03.31.21254518; this version posted April 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders Jan Wolff1,2,3, Pamela Reißner4, Gudrun Hefner5, Claus Normann2, Klaus Kaier6, Harald Binder6, Christoph Hiemke7, Sermin Toto8, Katharina Domschke2, Michael Marschollek1, Ansgar Klimke4,9 1 Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Germany. 2 Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 3 Evangelical Foundation NeuerKerode, Germany. 4 Vitos Hochtaunus, Friedrichsdorf, Germany. 5 Vitos Clinic for Forensic Psychiatry, Eltville, Germany 6 Institute of Medical Biometry and Statistics, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany. 7 Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Germany. 8 Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Germany. 9 Heinrich-Heine-University Düsseldorf, Germany. ___ Correspondence Dr. Jan Wolff, Peter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Hannover, Germany. Address: Karl- Wiechert-Allee 3, 30625 Hannover. Email: [email protected], wolff.jan@mh- hannover.de, ORCID: https://orcid.org/0000-0003-2750-0606 Key words (MeSH) Depression, Polypharmacy, Antidepressants, Hospitals, Drug Interactions, Psychiatry NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Antipsychotics
    The Fut ure of Antipsychotic Therapy (page 7 in syllabus) Stepp,,hen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry Universityyg of California, San Diego School of Medicine Honorary Visiting Senior Fellow, Cambridge University, UK Sppyonsored by the Neuroscience Education Institute Additionally sponsored by the American Society for the Advancement of Pharmacotherapy This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. Copyright © 2011 Neuroscience Education Institute. All rights reserved. Individual Disclosure Statement Faculty Editor / Presenter Stephen M. Stahl, MD, PhD, is an adjunct professor in the department of psychiatry at the University of California, San Diego School of Medicine, and an honorary visiting senior fellow at the University of Cambridge in the UK. Grant/Research: AstraZeneca, BioMarin, Dainippon Sumitomo, Dey, Forest, Genomind, Lilly, Merck, Pamlab, Pfizer, PGxHealth/Trovis, Schering-Plough, Sepracor/Sunovion, Servier, Shire, Torrent Consultant/Advisor: Advent, Alkermes, Arena, AstraZeneca, AVANIR, BioMarin, Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, CeNeRx, Cypress, Dainippon Sumitomo, Dey, Forest, Genomind, Janssen, Jazz, Labopharm, Lilly, Lundbeck, Merck, Neuronetics, Novartis, Ono, Orexigen, Otsuka, Pamlab, Pfizer, PGxHealth/Trovis, Rexahn, Roche, Royalty, Schering-Plough, Servier, Shire, Solvay/Abbott, Sunovion/Sepracor, Valeant, VIVUS, Speakers Bureau: Dainippon Sumitomo, Forest, Lilly, Merck, Pamlab, Pfizer, Sepracor/Sunovion, Servier, Wyeth Copyright © 2011 Neuroscience Education Institute. All rights reserved. Learninggj Objectives • Differentiate antipsychotic drugs from each other on the basis of their pharmacological mechanisms and their associated therapeutic and side effects • Integrate novel treatment approaches into clinical practice according to best practices guidelines • Identify novel therapeutic options currently being researched for the treatment of schizophrenia Copyright © 2011 Neuroscience Education Institute.
    [Show full text]
  • Emea/666243/2009
    European Medicines Agency London, 29 October 2009 EMEA/666243/2009 ISSUE NUMBER: 0910 MONTHLY REPORT PHARMACOVIGILANCE WORKING PARTY (PHVWP) OCTOBER 2009 PLENARY MEETING The CHMP Pharmacovigilance Working Party (PhVWP) held its October 2009 plenary meeting on 19-21 October 2009. PhVWP DISCUSSIONS ON SAFETY CONCERNS Below is a summary of the discussions regarding non-centrally authorised medicinal products in accordance with the PhVWP publication policy (see under http://www.emea.europa.eu/htms/human/phv/reports.htm). Positions agreed by the PhVWP for non- centrally authorised products are recommendations to Member States. For safety updates concerning centrally authorised products and products subject to ongoing CHMP procedures, readers are referred to the CHMP Monthly Report (see under http://www.emea.europa.eu/pressoffice/presshome.htm). The PhVWP provides advice on these products to the Committee of Medicinal Products for Human Use (CHMP) upon its request. Antipsychotics - risk of venous thromboembolism (VTE) Identify risk factors for VTE for preventive action before and during treatment with antipsychotics The PhVWP completed their review on the risk of VTE of antipsychotics1. The review was triggered by and based on data from the UK spontaneous adverse drug reactions reporting system and the published literature. The PhVWP carefully considered the data, including the limitations of both information sources, such as the lack of randomised controlled trial data, the heterogeneity of published studies and the potential confounding factors such as sedation and weight gain, commonly present in antipsychotic users. The PhVWP concluded that an association between VTE and antipsychotics cannot be excluded. Distinguishing different risk levels between the various active substances was not possible.
    [Show full text]
  • Pharmacokinetic Considerations in Antipsychotic Augmentation Strategies: How to Combine Risperidone with Low-Potency Antipsychotics
    Progress in Neuro-Psychopharmacology & Biological Psychiatry 76 (2017) 101–106 Contents lists available at ScienceDirect Progress in Neuro-Psychopharmacology & Biological Psychiatry journal homepage: www.elsevier.com/locate/pnp Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics Michael Paulzen a,b,1, Georgios Schoretsanitis a,b,f,⁎,1, Benedikt Stegmann d,ChristophHiemkeg,h, Gerhard Gründer a,b,KoenR.J.Schruerse, Sebastian Walther f, Sarah E. Lammertz a,b,EkkehardHaenc,d a Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, Germany b JARA – Translational Brain Medicine, Aachen, Germany c Clinical Pharmacology, Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany d Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany e Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands f University Hospital of Psychiatry, Bern, Switzerland g Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Germany h Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Germany article info abstract Article history: Objectives: To investigate in vivo the effect of low-potency antipsychotics on metabolism of risperidone (RIS). Received 22 December 2016 Methods: A therapeutic drug monitoring database containing plasma concentrations of RIS and its metabolite 9-OH- Accepted 12 March 2017 RIS of 1584 patients was analyzed. Five groups were compared; a risperidone group (n = 842) and four co- med- Available online 14 March 2017 ication groups; a group co-medicated with chlorprothixene (n = 67), a group with levomepromazine (n = 32), a group with melperone (n = 46), a group with pipamperone (n = 63) and a group with prothipendyl (n = 24).
    [Show full text]
  • Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gutlbrain Interaction): a Rome Foundation Working Team Report Douglas A
    Gastroenterology 2018;154:1140–1171 SPECIAL REPORT Neuromodulators for Functional Gastrointestinal Disorders (Disorders of GutLBrain Interaction): A Rome Foundation Working Team Report Douglas A. Drossman,1,2 Jan Tack,3 Alexander C. Ford,4,5 Eva Szigethy,6 Hans Törnblom,7 and Lukas Van Oudenhove8 1Center for Functional Gastrointestinal and Motility Disorders, University of North Carolina, Chapel Hill, North Carolina; 2Center for Education and Practice of Biopsychosocial Care and Drossman Gastroenterology, Chapel Hill, North Carolina; 3Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium; 4Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom; 5Leeds Gastroenterology Institute, St James’s University Hospital, Leeds, United Kingdom; 6Departments of Psychiatry and Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; 7Departments of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and 8Laboratory for BrainÀGut Axis Studies, Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium BACKGROUND & AIMS: Central neuromodulators (antide- summary information and guidelines for the use of central pressants, antipsychotics, and other central nervous neuromodulators in the treatment of chronic gastrointestinal systemÀtargeted medications) are increasingly used for treat- symptoms and FGIDs. Further studies are needed to confirm ment
    [Show full text]
  • Paliperidone Palmitate and Risperidone Long-Acting Injectable in Subjects with Schizophrenia Recently Treated with Oral Risperidone Or Other Oral Antipsychotics
    Neuropsychiatric Disease and Treatment Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics Larry Alphs1 Background: This post hoc subgroup analysis of a randomized, double-blind trial evaluated Cynthia A Bossie1 the response to treatment with two long-acting injectable atypical antipsychotics, ie, paliperi- Jennifer Kern Sliwa2 done palmitate and risperidone long-acting injectable (RLAI), in subjects with schizophrenia Dong-Jing Fu1 experiencing clinically significant symptoms despite recent treatment with oral risperidone only Yi-Wen Ma3 or other oral antipsychotics. Joseph Hulihan1 Methods: Adult subjects were eligible for the 13-week, double-blind, double-dummy trial (NCT00589914) if they had an established diagnosis of schizophrenia for at least one year and 1 2 For personal use only. CNS Medical Affairs, Medical a Positive and Negative Syndrome Scale (PANSS) total score of 60–120 inclusive at screening. Information, Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 3Biostatistics, Subjects received either paliperidone palmitate (234 mg, day 1; 156 mg, day 8; then once-monthly B&P, Janssen Research & Development flexible dosing) or RLAI (25–50 mg biweekly, with oral risperidone supplementation on days LLC, Titusville, NJ, USA 1–28), plus matched placebo injections/tablets. Results: This post hoc analysis reports data on 747 subjects who, within 2 weeks of starting double-blind study medication, had reportedly received oral risperidone only (paliperidone palmitate group, n = 126; RLAI group, n = 107), other oral antipsychotics (paliperidone palmitate group, n 199; RLAI group, n 203), or no antipsychotic (paliperidone palmitate group, n 56; Video abstract = = = RLAI group, n = 56).
    [Show full text]
  • Electronic Search Strategies
    Appendix 1: electronic search strategies The following search strategy will be applied in PubMed: ("Antipsychotic Agents"[Mesh] OR acepromazine OR acetophenazine OR amisulpride OR aripiprazole OR asenapine OR benperidol OR bromperidol OR butaperazine OR Chlorpromazine OR chlorproethazine OR chlorprothixene OR clopenthixol OR clotiapine OR clozapine OR cyamemazine OR dixyrazine OR droperidol OR fluanisone OR flupentixol OR fluphenazine OR fluspirilene OR haloperidol OR iloperidone OR levomepromazine OR levosulpiride OR loxapine OR lurasidone OR melperone OR mesoridazine OR molindone OR moperone OR mosapramine OR olanzapine OR oxypertine OR paliperidone OR penfluridol OR perazine OR periciazine OR perphenazine OR pimozide OR pipamperone OR pipotiazine OR prochlorperazine OR promazine OR prothipendyl OR quetiapine OR remoxipride OR risperidone OR sertindole OR sulpiride OR sultopride OR tiapride OR thiopropazate OR thioproperazine OR thioridazine OR tiotixene OR trifluoperazine OR trifluperidol OR triflupromazine OR veralipride OR ziprasidone OR zotepine OR zuclopenthixol ) AND ("Randomized Controlled Trial"[ptyp] OR "Controlled Clinical Trial"[ptyp] OR "Multicenter Study"[ptyp] OR "randomized"[tiab] OR "randomised"[tiab] OR "placebo"[tiab] OR "randomly"[tiab] OR "trial"[tiab] OR controlled[ti] OR randomized controlled trials[mh] OR random allocation[mh] OR double-blind method[mh] OR single-blind method[mh] OR "Clinical Trial"[Ptyp] OR "Clinical Trials as Topic"[Mesh]) AND (((Schizo*[tiab] OR Psychosis[tiab] OR psychoses[tiab] OR psychotic[tiab] OR disturbed[tiab] OR paranoid[tiab] OR paranoia[tiab]) AND ((Child*[ti] OR Paediatric[ti] OR Pediatric[ti] OR Juvenile[ti] OR Youth[ti] OR Young[ti] OR Adolesc*[ti] OR Teenage*[ti] OR early*[ti] OR kids[ti] OR infant*[ti] OR toddler*[ti] OR boys[ti] OR girls[ti] OR "Child"[Mesh]) OR "Infant"[Mesh])) OR ("Schizophrenia, Childhood"[Mesh])).
    [Show full text]
  • New Information of Dopaminergic Agents Based on Quantum Chemistry Calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A
    www.nature.com/scientificreports OPEN New information of dopaminergic agents based on quantum chemistry calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A. Ibarra3, Rubicelia Vargas4, Elisabeth Winnberg5 & Ana Martínez6* Dopamine is an important neurotransmitter that plays a key role in a wide range of both locomotive and cognitive functions in humans. Disturbances on the dopaminergic system cause, among others, psychosis, Parkinson’s disease and Huntington’s disease. Antipsychotics are drugs that interact primarily with the dopamine receptors and are thus important for the control of psychosis and related disorders. These drugs function as agonists or antagonists and are classifed as such in the literature. However, there is still much to learn about the underlying mechanism of action of these drugs. The goal of this investigation is to analyze the intrinsic chemical reactivity, more specifcally, the electron donor–acceptor capacity of 217 molecules used as dopaminergic substances, particularly focusing on drugs used to treat psychosis. We analyzed 86 molecules categorized as agonists and 131 molecules classifed as antagonists, applying Density Functional Theory calculations. Results show that most of the agonists are electron donors, as is dopamine, whereas most of the antagonists are electron acceptors. Therefore, a new characterization based on the electron transfer capacity is proposed in this study. This new classifcation can guide the clinical decision‑making process based on the physiopathological knowledge of the dopaminergic diseases. During the second half of the last century, a movement referred to as the third revolution in psychiatry emerged, directly related to the development of new antipsychotic drugs for the treatment of psychosis.
    [Show full text]
  • Therapies Under Investigation for Treating Parkinson's Disease
    Clinical Trial Outcomes Huynh & Huot Therapies under investigation for treating Par- kinson’s disease psychosis 4 Clinical Trial Outcomes Therapies under investigation for treating Parkinson’s disease psychosis Clin. Investig. (Lond.) Parkinson’s disease (PD) psychosis is a distressing condition that affects up to 60% of Niem Tu Huynh1 & Philippe patients at the advanced stages of the disease. It significantly impairs patients’ and Huot*,1,2,3 caregiver’s quality of life. Current therapeutic options are limited, and only clozapine 1Espera Neuroscience Inc., Montreal, QC, Canada and, more recently, pimavanserin were demonstrated to be effective in Phase III clinical 2Department of Pharmacology, Faculty trials. Phase II studies, open-label trials, case series and case reports have suggested an of Medicine, University of Montreal, anti-psychotic efficacy of donepezil, melperone, mianserin, mirtazapine, ondansetron, Montreal, QC, Canada quetiapine, rivastigmine and sarcosine. In contrast, aripiprazole, galantamine and 3Division of Neurology, Centre Hospitalier memantine do not appear effective to alleviate PD psychosis. This review article de l’Université de Montréal, Montreal, QC, Canada discusses some of the available therapies to treat PD psychosis and surveys drugs that *Author for correspondence: have recently undergone investigation, or that are presently being studied to address Tel.: 514 890 8000 this condition. Fax.: 514 412 7150 [email protected] Keywords: clozapine • donepezil • hallucinations • mirtazapine • Parkinson’s disease • pimavanserin • psychosis • quetiapine • rivastigmine • sarcosine The most recognizable manifestations of tions [15,16]. Some patients develop feelings of Parkinson’s disease (PD), bradykinesia, rest- presence [17] or paranoid delusions [18]. The ing tremor and rigidity [1–3], affect the motor occurrence of visual hallucinations precedes 10.4155/CLI.14.84 system.
    [Show full text]
  • Quantification of Neuroleptics in Human Plasma Or Serum by Liquid Chromatography-Tandem Mass Spectrometry for Clinical Research
    TECHNICAL NOTE 65134 Quantification of neuroleptics in human plasma or serum by liquid chromatography-tandem mass spectrometry for clinical research Authors Application benefits Claudio De Nardi, • Simple offline sample preparation by protein precipitation Thermo Fisher Scientific GmbH, • 28 neuroleptics in a single quantitative method Dreieich, Germany Sergio Indelicato, Introduction Thermo Fisher Scientific, An analytical method for clinical research, quantifying 28 neuroleptics Les Ulis, France in human plasma or serum, is reported. Analysis includes ziprasidone, paliperidone, flupenthixole, prothipendyl, aripiprazole, melperone, melperone, promethazine, levomepromazine, sulpiride, haloperidole, sertindole, perazine, zotepine, clozapine, risperidone, olanzapine, fluphenazine, Keywords dehydroaripiprazole, zuclopenthixole, pipamperone, norquetiapine, Neuroleptics, offline sample quetiapine, thioridazine, chlorprothixene, desmethylolanzapine, preparation, plasma, serum, mass chlorpromazine, and norclozapine. Plasma or serum samples are extracted spectrometry by offline internal standard addition and protein precipitation. Extracted samples are injected onto a Thermo Scientific™ Vanquish™ Flex Binary system connected to a Thermo Scientific™ TSQ Quantis™ triple quadrupole mass Goal spectrometer with heated electrospray ionization. Detection is performed by Implementation of an analytical selected reaction monitoring (SRM) using 25 deuterated internal standards. method for the quantification of Method performance was evaluated using the
    [Show full text]